BioLuminate Breast Cancer Detector R&D Delayed By Financing Drought
This article was originally published in The Gray Sheet
Executive Summary
BioLuminate will launch a 12-center, 1,000-patient Phase III pivotal trial to support a PMA application for its Smart Probe breast cancer detection tool as an adjunct to mammography, following completion of a 150-patient Phase I/II study later this year